Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a clinical syndrome characterized by pain, pressure, discomfort perceived to be related to the urinary bladder, associated with LUTS, in the absence of infection of other identifiable causes [1] . Our understanding of the aetiology and pathophysiology of IC/BPS is poor; treatments are often ineffective and lack durable response over time. An objective of the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal studies is to study mechanistic pathways and investigate potential therapeutic targets using animal models of pelvic pain [2] . In the present paper we report our findings on anti-vascular endothelial growth factor (VEGF)-neutralizing antibodies. VEGF is a pleiotropic cytokine traditionally known for its angiogenic activity [3] . Recent clinical studies showed that bladder and urinary VEGF expression is elevated among patients with IC/ BPS [4] [5] [6] , and that bladder and urinary expression levels correlated to the severity of pain [6, 7] . VEGF expression was reduced after onabotulinumtoxinA (Botox) injection into the bladder and improvement of the pain [8] . The potential link between VEGF and bladder pain is further supported by animal studies. Instillation of VEGF into the bladder lumen resulted in the development of pelvic hypersensitivity in mice [9] . Upregulation of VEGF in the bladder has also been observed in animals with cyclophosphamide (CYP) cystitis [10] . Taken together, these clinical and basic studies suggest that VEGF signalling might play a role in modulating bladder pain and bladder function. In the present study, we tested the hypothesis that treatment with anti-VEGF-neutralizing antibodies can reduce the pain and voiding dysfunction in the CYP cystitis model of bladder pain in mice.
Materials and Methods

Animals
Adult female C57BL/6J mice (8-10 weeks, 18-23 g, Jackson Laboratory, Bar Harbor, ME, USA) were bred in the animal housing facility. The mice were maintained on a 12-h light/ 12-h dark cycle, with free access to food and water. All experiments were performed in accordance with the guidelines of the National Institutes of Health and were approved by the Washington University Animal Care and Use Committee.
Anti-VEGF or Saline Pre-Treatment Followed by CYP Injection
The mice were divided into two groups. One group (n = 15) was pre-treated with i.p. anti-VEGF antibodies (10 mg/kg i.p. B20-4.1.1 VEGF mAb, provided courtesy of Genentech, South San Francisco, CA, USA) while the other group (n = 12) received saline pre-treatment (same volume and same time as anti-VEGF). A single injection of CYP (150 mg/kg i.p.; Sigma Aldrich, St Louis, MO, USA) was then administered 36 h later to induce CYP cystitis. Behavioural assessments were performed at baseline, 14 h after anti-VEGF or saline (control) injection, and 5 h, 48 h and 96 h after CYP administration. All behavioural testing was performed by observers blind to treatment. Additional functional and structural information of the B20-4 anti-VEGF-neutralizing antibodies was described in Fuh et al. (2006) [11] .
Behavioural Tests
Pelvic Nociceptive Response Using von Frey Filaments
The mice were placed individually in Plexiglas cubicles on a wire grid on a raised platform in a room with white noise emitted from a noise generator. The mice were allowed to acclimate to the environment for a minimum of 30 min before behavioural testing. Mechanical stimulation was applied vertically to the lower abdominal/pelvic area close to the bladder, using four graduated von Frey filaments with strengths of 0.02 g, 0.08 g, 0.32 g and 1.28 g (North Coast Medical, San Jose, CA, USA), in ascending order of strength. Each filament was applied for 1-2 s, for a total of 10 times, at intervals 5-10 s apart. Different areas within this suprapubic region were stimulated to avoid desensitization or 'wind-up'. Withdrawal or retraction of the lower abdominal/ pelvic area from the filament stimulation was considered a positive nociceptive response. Data were expressed as the number of positive response out of 10 stimulations with each filament. To access the changes in withdrawal response to the whole range of filaments, the area under the curve (AUC) was also calculated for each animal and the average AUC for each treatment group was calculated. The AUC was calculated using the area of the trapezoid (the sum of the rectangle and triangle) between the points for each filament, as previously described [12] . For the present study, we used referred hypersensitivity instead of visceromotor response [13] to test for pelvic hypersensitivity because visceromotor response does not permit repeated measurements in the same animal over time.
Spontaneous Micturition Assessment Using Void Spot Assays
Urinary frequency and mean voided volume were studied using the void spot assay (VSA) [14] . Because C56BL/6J mice tend to urinate repeatedly in the corner of rectangular cages [14] , we modified the VSA technique to a circular area. Individual mice were gently removed from standard polycarbonate communal cages and placed into a circular mouse metabolic cage with precut circular-shaped filter paper (Fisher Scientific, Pittsburgh, PA; catalogue no. 05-714-4) taped to the bottom. Mice were provided with standard dry mouse chow for the duration of the assay, but water was withheld during the testing period because water dripping from the bottle was found to impair the integrity of the filter paper and altered urine spot dimensions. The micturition cages were kept in a quiet area for 2 h. Placement of mice into and removal from cages was done calmly to avoid startling the animal and causing reflex urination. At the end of the 2 h, the mouse was returned to normal housing, the filter paper was retrieved from the cage, and urine spots on the filter paper were imaged using ultraviolet light on a trans illuminator (Fig. 1A) . Because urinary frequency of C57BL/6J mice varies with respect to the time of day (e.g. increased frequency at night) [14] , we performed the VSA experiments at approximately the same time every afternoon between 13:00 and 17:00 h.
Image Analysis of VSA Data
Images were analysed using the Fiji version of IMAGEJ software. Scale was determined from images using a scale ruler (2.4 cm long; Fig. 1A ). The global option was selected, and images were converted to a stack, inverted, autothresholded, and converted to binary. Thresholded images in the stack were inspected for artifacts and were individually corrected if thresholding had omitted areas of urine or highlighted tape marks (Fig. 1B) . Using the 'analyse particles' function, excluding all particles with area <0.08 cm 2 (which corresponded to 0.5 lL of urine) faithfully captured urine spots. This threshold area was chosen to exclude small bright spots or 'particles' that might be from claw marks, tooth marks, footprints or tail dragging, as previously described by Yu et al. (2014) [14] . Urinary frequency was defined as the number of urine spots identified on a filter over the 2-h duration of testing. Urinary frequency data were quantified by two independent observers and averaged. Micturition volumes were determined using an area-to-volume standard curve as shown in Fig. 1C and D. We used VSA instead of awake cystometry for this study since VSA permits non-invasive and repeated measurement of spontaneous micturition in the same animal over time and does not involve surgical implantation of a catheter or the development of bladder inflammation. The VSA was used instead of metabolic cages because in our experience mice with CYP-induced cystitis void at very small volumes (≤10 lL) that are often below the level of detection of a standard mouse metabolic cage.
Statistical Analysis
The results are expressed as mean AE SEM values. Analyses were performed using PRISM version 6 (GraphPad, San Diego, CA). Repeated measures one-way ANOVA was used to compare the five time points within each treatment group (Fig. 2B and D) . 
Results
Cyclophosphamide Cystitis-Induced Pelvic Hypersensitivity
The stimulus-response curve to von Frey filaments was plotted and the AUC in the saline pre-treatment (control) experiments (n = 6) calculated ( Fig. 2A and B) . A single i.p. administration of CYP induced referred mechanical allodynia in the suprapubic area at 5, 48 and 96 h post-CYP administration ( Fig. 2A) . Pelvic hypersensitivity was reflected as a significant increase in the AUC in Fig. 2B at 5, 48 and 96 h compared with the baseline (P = 0.026, 0.0031 and 0.0003, respectively). There was no attenuation of AUC from 5 to 48 and 96 h post-CYP administration (P > 0.05).
Anti-VEGF Pre-treatment Reduced CYP-Induced Pelvic Hypersensitivity
The stimulus-response curve was plotted and the AUC in the anti-VEGF pre-treatment experiments (n = 7) calculated ( Fig. 2C and D) . Anti-VEGF itself has no impact on pelvic hypersensitivity (no difference in AUC from baseline; P = 0.89 [ Fig. 2D]) . Compared with baseline, there was a significant increase in AUC at 5 h post-CYP (P = 0.004); however, by 48 and 96 h post-CYP administration, pelvic hypersensitivity had reduced by 54% and 47%, respectively, compared with the 5 h post-CYP time point, and was no longer significantly different from baseline (P = 0.22 for the 48 h vs baseline comparison; and P = 0.17 for 96 h vs baseline).
Comparison Between the Anti-VEGF and Saline PreTreatment Groups Figure 2E shows the comparison of the AUCs in the two treatment groups at various time points. There were no differences between the groups at baseline and 5 h post-CYP; however, mice pre-treated with anti-VEGF had significantly less pelvic hypersensitivity at 48 and 96 h post-CYP administration compared with mice pre-treated with saline (P = 0.002 at 48 h; P = 0.011 at 96 h). In conclusion, the pelvic hypersensitivity induced by CYP cystitis was significantly reduced by pre-treatment with anti-VEGF antibodies compared with saline (control).
Effect of Anti-VEGF on Spontaneous Micturition Behaviour
When we compared the effects of anti-VEGF with those of saline pre-treatment on spontaneous micturition behaviour using the VSA, we found no difference in urinary frequency or mean voided volume between the two groups post-CYP administration (n = 8 for anti-VEGF group, n = 6 for saline group; P > 0.05 [ Fig. 3C and D] ). Representative blots are shown in Fig. 3A and B. Thus, anti-VEGF pre-treatment did not reduce CYP-induced micturition dysfunction.
Discussion
One challenge to the clinical management of IC/BPS is poor understanding of the mechanistic pathways and therapeutic targets involved in pelvic pain. The MAPP Research Network supports animal studies to address this research gap [2] . This pre-clinical study showed that systemic treatment with anti-VEGF antibodies was effective in reducing referred hypersensitivity in the acute CYP cystitis model of bladder pain. Anti-VEGF antibodies have traditionally been studied within the context of anti-angiogenesis and cancer treatment.
To our knowledge, this is the first study to show the potential of anti-VEGF-neutralizing antibodies in the treatment of visceral pain in general, and bladder pain specifically. Anti-VEGF monoclonal antibodies (bevacizumab) and antibody derivatives (ranibizumab) are clinically approved and currently available for the treatment of certain human conditions, such as advanced cancers and macular degeneration [15, 16] , making these compounds of particular interest for translational research. Our proof-of-concept data support further investigation of the use of anti-VEGF antibodies to manage bladder pain or visceral pain conditions in future studies.
VEGF receptors (VEGF-R1, VEGF-R2) and their coreceptors, the neuropilins (Nrp-1, Nrp-2) are expressed at high levels in the human bladder urothelium [17] . Recent clinical studies showed that tissue and urinary VEGF levels are elevated among patients with IC/BPS, and VEGF levels are positively correlated to the severity of bladder pain in patients [4] [5] [6] [7] . Intravesical instillation of VEGF resulted in an increase in bladder sensory fibre density, upregulation of voltage-gated sodium channels in lumbosacral dorsal root ganglia, and development of pelvic hypersensitivity in mice [9] . Upregulation of VEGF in the bladder has also been observed in animals with CYP cystitis [10] . Acrolein, the urinary metabolite of CYP, damages the urothelial integrity and causes chemical cystitis of the bladder. In the present study, systemic inhibition of VEGF signalling with anti-VEGF-neutralizing antibodies reduced pelvic hypersensitivity in an inflammatory model of bladder pain in mice. Collectively, these data are consistent with the hypothesis that VEGF signalling plays a mechanistic role in modulating bladder nociception.
Exactly how VEGF modulates bladder pain remains to be elucidated. VEGF is a pleiotropic cytokine traditionally known for its angiogenic activity [3] . VEGF levels are usually elevated at the site of tissue inflammation. VEGF enhances endothelial permeability, vasodilation, tissue oedema and macrophage recruitment, all part of the inflammatory response. VEGF is also involved in the pathogenesis of chronic inflammatory conditions such as atherosclerosis and inflammatory bowel disease [18, 19] . Upregulation of VEGF-164, VEGF-R2 receptors, and Npn-1, Npn-2 co-receptors has been observed after acute and chronic CYP cystitis [10] .
Besides inflammation, tissue hypoxia is the main physiological stimulus that upregulates VEGF. Bladder VEGF has been shown to be elevated in an animal model of pelvic ischaemia [20] . Prior bladder blood flow studies using endoscopic laser Doppler flowmetry also showed that bladder perfusion decreases with bladder filling in patients with IC/BPS but increases in control subjects without IC/BPS [21, 22] . These findings raise questions about whether IC/BPS might represent a chronic microvascular ischaemic condition, and whether the hypoxia that develops during bladder filling might contribute to visceral pain and VEGF expression in patients.
Other animal studies have also shown that VEGF may modulate pelvic pain by enhancing peripheral neuroplasticity. Intravesical instillation of VEGF has been shown to be associated with increased density of both sensory (TRPV-1) and motor (ChAT) nerve fibres in the bladder, and upregulation of voltage-gated sodium channels in lumbosacral dorsal root ganglia innervating the bladder [9] .
At this time, it is unclear mechanistically how anti-VEGFneutralizing antibodies might modulate pelvic pain. Most of the published literature on anti-VEGF antibodies has focused on anti-angiogenesis and cancer treatment. Surprisingly, there is very little literature on the use of anti-VEGF to treat bladder pain or visceral pain. Blockade of VEGF signalling shows some promise for the management of inflammatory joint pain. Intra-articular injection of bevacizumab is effective in the treatment of osteoarthritis [23] . Pre-treatment with anti-VEGF (B20) also blunted the chemical injury effects from intravesical BCG instillation [24] . In the present study, pre-treatment with anti-VEGF (B20) prior to CYP administration was effective in reducing the nociceptive response to von Frey filament stimulation while pre-treatment with saline (control) was not effective.
It is less clear whether VEGF might also play a role in modulating voiding function. In the present study, systemic anti-VEGF was not effective in normalizing the increased urinary frequency or increase in small voided volumes that developed after CYP cystitis; however, Malykhina et al. [9] have shown that local instillation of VEGF into the bladder lumen of na€ ıve mice reduced inter-micturition interval and bladder capacity during awake cystometry. In their study, the effects on cystometry were observed after 2 weeks of intravesical VEGF instillation but not after 1 week of intravesical VEGF instillation. It is unclear whether the differences between the two studies might be attributable to different experimental paradigms (local VEGF stimulation vs systemic anti-VEGF inhibition), different models used (na€ ıve mice vs CYP cystitis), different methodologies to measure micturition (cystometry vs spontaneous voiding measured by VSA, see discussion below), different duration of exposure (biweekly VEGF instillation vs a single acute exposure of anti-VEGF), or to the fact that VEGF signalling is differentially involved in the bladder pain vs voiding.
The present study has several limitations. Firstly, we acknowledge that the CYP cystitis model is not an animal model of IC/BPS; however, it is one of the most widely used and best characterized models with which to study inflammatory bladder pain. The CYP model recapitulates many of the key symptomatology of IC/BPS, for example, pain associated with bladder distention [13] , referred tactile allodynia to the suprapubic area [25, 26] , spontaneous painful behaviours [25] , urinary frequency [25, 27] , and bowelbladder cross-talk [27] (see reference 2 for more detailed discussion of the validity of the model). We chose this model for our initial proof-of-concept experiments because upregulation of VEGF signalling has previously been demonstrated in CYP cystitis [10] , so this is a reasonable model with which to examine the effects of anti-VEGF treatment, recognizing that the findings may not translate to the human condition (IC/BPS). In future studies we plan to examine the anti-VEGF effects in other bladder pain models. Secondly, although the VSA method is advantageous to metabolic cages (e.g. sensitive to volumes ≤10 lL) or awake cystometry (e.g. no invasive surgery to implant suprapubic catheter and no bladder inflammation), the VSA method has its own limitations. For example, overlapping voids in the same area of the filter paper may not be quantified correctly, and the VSA does not provide information on bladder pressures. Although a previous study showed that VSA patterns correlated reasonably well to baseline pressure, threshold pressure and intermicturition pressure [28] , caveats in the methodologies (VSA vs cystometry) may explain the differences in micturition results between the present study and those of the study by Malykhina et al. [9] . Thirdly, we have not examined the bladder histology or urinary markers of inflammation and hypoxia in the present study. These will be investigated in the future to characterize the histological and urinary effects of anti-VEGF treatment.
In conclusion, systemic treatment with anti-VEGF-neutralizing antibodies was effective in reducing pelvic/bladder pain in the CYP cystitis model of bladder pain in mice. Our data support further investigation of the use of anti-VEGF antibodies to manage bladder pain or visceral pain in future studies.
